Overview
NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease. This is because Bayer did not provide an evidence submission.
Last reviewed: 25 February 2015
Next review: We will review this decision if the company decides to make a submission.